1 | Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. (Rahmouni K, Morgan DA, Morgan GM, Liu X, Sigmund CD, Mark AL, Haynes WG) J Clin Invest 2004 Sep;114(5):652-8 174 Citations |
2 | Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27. (Rafiee P, Theriot ME, Nelson VM, Heidemann J, Kanaa Y, Horowitz SA, Rogaczewski A, Johnson CP, Ali I, Shaker R, Binion DG) Am J Physiol Cell Physiol 2006 Nov;291(5):C931-45 79 Citations |
2 | Deletion of PI3K-p85alpha gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells. (Awasthi A, Samarakoon A, Dai X, Wen R, Wang D, Malarkannan S) Genes Immun 2008 Sep;9(6):522-35 29 Citations |
1 | The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. (Guo H, Samarakoon A, Vanhaesebroeck B, Malarkannan S) J Exp Med 2008 Sep 29;205(10):2419-35 90 Citations |
1 | Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. (Bodiga S, Zhang R, Jacobs DE, Larsen BT, Tampo A, Manthati VL, Kwok WM, Zeldin DC, Falck JR, Gutterman DD, Jacobs ER, Medhora MM) J Mol Cell Cardiol 2009 Jun;46(6):978-88 45 Citations |
2 | PI3Kbeta goes to the head of its class. (Newman DK) Blood 2009 Sep 03;114(10):2011-2 1 Citation |
1 | Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways. (Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, Zarbock A) Blood 2010 Apr 15;115(15):3118-27 138 Citations |
1 | NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. (Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S) Mol Cancer 2010 Apr 30;9:97 100 Citations |
1 | Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. (Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu F, Huang YW, Liyanarachchi S, Deatherage DE, Hsu PY, Taslim C, Ramaswamy B, Shapiro CL, Lin HJ, Cheng AS, Jin VX, Huang TH) Cancer Res 2011 Mar 01;71(5):1752-62 52 Citations |
1 | PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. (Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R) Mol Cancer Ther 2011 Mar;10(3):558-65 308 Citations |
1 | Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. (Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM) Cancer Res 2011 Sep 15;71(18):5965-75 14 Citations |
1 | Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. (Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW) Clin Cancer Res 2012 Mar 01;18(5):1464-71 97 Citations |
1 | PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. (Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R) J Clin Oncol 2012 Mar 10;30(8):777-82 405 Citations |
1 | Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling. (Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH) Blood 2012 Jul 26;120(4):868-79 45 Citations |
1 | PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. (Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R) Cancer Res 2013 Jan 01;73(1):276-84 254 Citations |
1 | Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer. (Fox EM, Arteaga CL, Miller TW) Front Oncol 2012;2:145 |
1 | Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. (Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R) J Clin Oncol 2013 Mar 20;31(9):e137-40 28 Citations |
1 | Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. (Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R) Cell Rep 2014 Jan 30;6(2):377-87 206 Citations |
1 | Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. (Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R) Oncotarget 2014 May 30;5(10):3029-38 39 Citations |
1 | Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. (Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R) Oncotarget 2014 May 30;5(10):3012-22 82 Citations |
1 | Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. (Hosford SR, Miller TW) Pharmgenomics Pers Med 2014;7:203-15 132 Citations |
1 | P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. (Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW) Oncogene 2015 Jul 23;34(30):3968-76 67 Citations |
1 | Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. (Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S) Oncotarget 2014 Nov 30;5(22):11168-79 56 Citations |
1 | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. (Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW) Breast Cancer Res Treat 2015 Jan;149(1):69-79 14 Citations |
1 | PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. (Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA) Oncogenesis 2015 Oct 05;4(10):e169 54 Citations |
1 | Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. (Yueh AE, Payne SN, Leystra AA, Van De Hey DR, Foley TM, Pasch CA, Clipson L, Matkowskyj KA, Deming DA) PLoS One 2016;11(2):e0148730 16 Citations |
1 | Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. (Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F) Oncoscience 2016;3(5-6):164-72 37 Citations |
1 | Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. (Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL) JAMA Oncol 2017 Apr 01;3(4):509-515 164 Citations |
1 | Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations. (Foley TM, Payne SN, Pasch CA, Yueh AE, Van De Hey DR, Korkos DP, Clipson L, Maher ME, Matkowskyj KA, Newton MA, Deming DA) Mol Cancer Res 2017 Feb 09;15(3):317-327 46 Citations |
1 | Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. (Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T) Oncotarget 2017 Jul 25;8(30):49253-49263 12 Citations |
1 | In silico binding affinity studies of N-9 substituted 6-(4-(4-
propoxyphenyl)piperazin-1-yl)-9H-purine derivatives-Target
for P70-S6K1 & PI3K-d kinases () Beni-Suef University Journal of Basic and Applied Sciences |
1 | Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. (Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW) Oncotarget 2018 Feb 06;9(10):8810-8822 14 Citations |
2 | Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. (Hsu AH, Lum MA, Shim KS, Frederick PJ, Morrison CD, Chen B, Lele SM, Sheinin YM, Daikoku T, Dey SK, Leone G, Black AR, Black JD) Cell Rep 2018 Jul 17;24(3):655-669 37 Citations |
3 | Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. (Shah NN, Jerkins JH, Johnson BD, Hari P) JCO Oncol Pract 2020 Sep;16(9):613-614 2 Citations |
1 | Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. (Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP) Cancers (Basel) 2020 Aug 15;12(8) 55 Citations |
1 | Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. (Dou R, Qian J, Wu W, Zhang Y, Yuan Y, Guo M, Wei R, Yang S, Jurczyszyn A, Janz S, Beksac M, Gu C, Yang Y) Cell Death Dis 2021 Feb 24;12(2):206 16 Citations |
1 | Inhibition of PI3K/mTOR/KATP channel blunts sodium thiosulphate preconditioning mediated cardioprotection against ischemia-reperfusion injury. (Boovarahan SR, Venkatasubramanian H, Sharma N, Venkatesh S, Prem P, Kurian GA) Arch Pharm Res 2021 Jun;44(6):605-620 4 Citations |
1 | Preconditioning the rat heart with 5-azacytidine attenuates myocardial ischemia/reperfusion injury via PI3K/GSK3β and mitochondrial KATP signaling axis. (Boovarahan SR, Kurian GA) J Biochem Mol Toxicol 2021 Dec;35(12):e22911 18 Citations |
7 | Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers February-2 2022;14(4) 15 Citations |
9 | Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers (Basel) 2022 Feb 15;14(4) 15 Citations |
6 | Correction to: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (Cancers, (2022), 14, 958) (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers May-2 2022;14(10) 2 Citations |
1 | Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. (Song Y, Bugada L, Li R, Hu H, Zhang L, Li C, Yuan H, Rajanayake KK, Truchan NA, Wen F, Gao W, Sun D) Sci Transl Med 2022 May 04;14(643):eabl3649 63 Citations |
9 | Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14, 958. (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P) Cancers (Basel) 2022 May 16;14(10) 2 Citations |
1 | Alpelisib Efficacy without Cherry-PI3King Mutations. (Tau S, Miller TW) Clin Cancer Res 2023 Mar 14;29(6):989-990 1 Citation |
1 | PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis. (Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR) Clin Cancer Res 2023 Jul 05;29(13):2375-2384 5 Citations |
1 | Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. (Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK) Cancer Res Commun 2023 Nov 20;3(11):2358-2374 4 Citations |
6 | In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations. (Zenga J, Himburg HA, Wong SJ, Kearl T, Hematti P, Jin VX, Memon AA, Mathison AJ, Awan MJ) Oral Oncol 2024 Sep;156:106947 |
5 | In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations (Zenga J, Himburg HA, Wong SJ, Kearl T, Hematti P, Jin VX, Memon AA, Mathison AJ, Awan MJ) Oral Oncology September 2024;156 |
1 | Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3Kδ syndrome. (Remiker AS, Lopes JPM, Jesudas R, Superdock A, Park N, Pateva I) Front Pediatr 2024;12:1494945 |
1 | PI3K signaling and lysyl oxidase is critical to corneal stroma fibrosis following mustard gas injury. (Sinha NR, Hofmann AC, Suleiman LA, Laub R, Tripathi R, Chaurasia SS, Mohan RR) Exp Eye Res 2025 Feb;251:110213 |